Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Data from an ongoing study suggests that the drug, combined with an androgen receptor signaling inhibitor, may be efficacious in a particularly hard to treat form of prostate cancer.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
